Triple negative breast cancer (TNBC) accounts for ~15–20% of incident breast cancers and is characterized by negativity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.